Clara Ugolini

BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study

Rossella Elisei, Clara Ugolini, David Viola et al. · The Journal of Clinical Endocrinology & Metabolism · 2008 · 525 citations

Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma

Cristiana Lupi, Riccardo Giannini, Clara Ugolini et al. · The Journal of Clinical Endocrinology & Metabolism · 2007 · 393 citations · Full text

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role

Emilio Fiore, Teresa Rago, M A Provenzale et al. · Endocrine Related Cancer · 2009 · 247 citations · Full text

Thyroid Nodules, Higher Tsh Values, Iodine Deficiency Disorders +10

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 246 citations · Full text

Oncology, Clinical Trials, Colorectal Cancer +9